Su­per­nus bat­tles back from CRL, scor­ing the FDA's ap­proval for non-stim­u­lant AD­HD med Qel­bree

Af­ter a harsh slap­down last fall, US reg­u­la­tors are now singing a dif­fer­ent tune on Su­per­nus Phar­ma­ceu­ti­cals’ “sprin­kleable” AD­HD drug.

The FDA on Fri­day ap­proved …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER